



FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST – January 31, 2008

2008 CORPORATE MEMBERSHIP/SUPPORTER NEWS:

FLASCO is pleased to announce that **Bayer** has renewed its Platinum Membership for 2008. THANKS **Bayer!**

MEMBERSHIP:

Reminder – Your 2008 FLASCO dues were payable on or before January 1, 2008. A special thanks to those who have paid their dues. A Second Notice has been mailed to all who have not paid according to our records. If you think you have paid and you receive a letter please contact the FLASCO Executive Director.

ASH UPDATES:

Register for Highlights of ASH

Don't miss Highlights of ASH in either Seattle, WA, on February 1-2 or in Austin, TX, on February 8-9. During these meetings you will hear renowned experts present their analyses of the most influential studies from the 2007 ASH Annual Meeting. Don't delay – register today. The link to register is <https://store.hematology.org/default.aspx?tabid=85>.

FCSO UPDATES

Line Item Billing Requirement for End Stage Renal Disease Claims (PART A)

[MM5039] Last Modified: 1/25/2008 CMS has revised this MLN Matters article to add references to change requests 5768 and 5545. All other information remains unchanged.
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5039.pdf>

Clarification of Patient Discharge Status Codes and Hospital Transfer Policies (PART A)

[SE0801] Last Modified: 1/25/2008 - Guidelines to determine the correct two-digit patient discharge status code. Choosing the patient discharge status code correctly avoids claim errors and helps providers receive payment for their claim sooner.
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/SE0801.pdf>

Use of an Eight-Digit Registry Number on Clinical Trial Claims (PART A & B)

[MM5790] Last Modified: 1/23/2008 - Providers may voluntarily report on the Medicare claim forms the eight-digit clinical trial number assigned by the National Library of Medicine Clinical Trial Data Bank when a sponsor or investigator registers a new study.
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5790.pdf>

New HCPCS Modifiers when Billing for Patient Care in Clinical Research Studies (PART A & B)

[MM5805] - Last Modified: 1/23/2008 - Two new modifiers, Q0 and Q1, have been created to differentiate between routine and investigational clinical services effective for dates of service on and after January 1, 2008, replacing discontinued modifiers QA, QR and QV.
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5805.pdf>

January 2008 Integrated Outpatient Code Editor Specifications Version 9.0 – (PART A)

[MM5865] - Last Modified: 1/23/2008 - Status indicator for brachytherapy and radiopharmaceutical codes has been changed from K to H for dates of service of January 1, 2008, through June 30, 2008, as a result of new legislation.
<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5865.pdf>

January 2008 Medicare A & B Bulletin Special Issue - Last Modified: 1/25/2008

Draft local coverage determinations for Medicare Part A & Part B providers are now available for review and comments. Web site <http://www.floridamedicare.com>

FDA UPDATES:

New Genetic Test For Breast Cancer Patients Approved by the FDA (01/25/2008)

The United States Food and Drug Administration (FDA) has recently approved the TOP2A FISH pharmDx test, a genetic test to help assess risk of breast cancer recurrence and long-term survival for early breast cancer patients. The TOP2A FISH pharmDx test is approved for breast cancer patients who are considered to have a moderate to high risk of developing a recurrence

Syringe Recall:

FDA has announced a nationwide recall of **all lots of heparin and saline pre-filled flush syringes manufactured by AM2 PAT, Inc. under the brand names Sierra Pre-filled, Inc. and B. Braun.** Two lots have been found to be contaminated with *Serratia marcescens*, a bacterium that can cause serious injury or death. The syringes are sold in fill sizes of 3mL, 5mL and 10mL and syringe sizes of 6mL and 12mL.

<http://www.fda.gov/bbs/topics/NEWS/2008/NEW01785.html>

FDA approves Merck & Co.'s Emend injection

Merck & Co. announced Tuesday that the FDA approved its Emend for injection, in combination with other antiemetics, for the prevention of nausea and vomiting induced by chemotherapy. The drug is also marketed in an oral formulation

SPECIAL NOTE:

Please see the new employment opportunity on the FLASCO Website. WWW.FLASCO.ORG

CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2008)

FLASCO Members extends a big thanks to all of our 2008 Corporate Members/Sponsors

PLATINUM

Astra Zeneca
Bayer
Cephalon
Eli Lilly
Oncology Supply/ION
Sanofi-Aventis
OPR
Pharmion

GOLD

Celgene
Genomic Health

SILVER

MGI Pharma
US Oncology Physician Services

BRONZE

Boehringer Ingelheim
Pharmaceuticals, Inc.
Alexion

FLASCO EVENTS:

March 7-8, 2008 – FLASCO Spring Meeting – Tampa Airport Marriott Hotel

November 7-8, 2008 – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

FLASCO Contact Information:

Dorothy Green Phillips, Executive Director - 3709 W. Jetton Ave., Tampa, Florida 33629
Tel: 800.444.1410, Ext. 4410 - Cell Phone: 813.294.2620 - Fax: 813.254.5857 or 813.349.4472
Email: Dorothy.Green@cancer.org